Pfizer Inc. (NYSE:PFE) Shares Purchased by Walled Lake Planning & Wealth Management LLC

Key Points

• Walled Lake Planning & Wealth Management LLC increased its stake in Pfizer Inc. by 204.2%, acquiring an additional 83,681 shares during the 1st quarter, making Pfizer its 27th largest holding.
• Pfizer reported a quarterly EPS of $0.92, exceeding expectations, though its revenue fell by 7.8% year-over-year, totaling $13.72 billion.
• The company declared a quarterly dividend of $0.43, translating to an annualized yield of 7.07%, with a payout ratio of 124.64%.

Walled Lake Planning & Wealth Management LLC lifted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 204.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 124,668 shares of the biopharmaceutical company's stock after acquiring an additional 83,681 shares during the period. Pfizer accounts for approximately 1.1% of Walled Lake Planning & Wealth Management LLC's investment portfolio, making the stock its 27th biggest holding. Walled Lake Planning & Wealth Management LLC's holdings in Pfizer were worth $3,159,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the business. Harvest Fund Management Co. Ltd boosted its holdings in Pfizer by 12,069.0% in the first quarter. Harvest Fund Management Co. Ltd now owns 7,058 shares of the biopharmaceutical company's stock valued at $179,000 after purchasing an additional 7,000 shares during the last quarter. S&CO Inc. boosted its stake in shares of Pfizer by 402.1% during the 1st quarter. S&CO Inc. now owns 58,749 shares of the biopharmaceutical company's stock worth $1,488,000 after acquiring an additional 47,049 shares in the last quarter. Banque Cantonale Vaudoise purchased a new stake in shares of Pfizer during the 1st quarter worth about $6,595,000. GSA Capital Partners LLP boosted its stake in shares of Pfizer by 513.6% during the 1st quarter. GSA Capital Partners LLP now owns 122,036 shares of the biopharmaceutical company's stock worth $3,092,000 after acquiring an additional 102,148 shares in the last quarter. Finally, Federated Hermes Inc. boosted its stake in shares of Pfizer by 22.2% during the 1st quarter. Federated Hermes Inc. now owns 17,592,709 shares of the biopharmaceutical company's stock worth $445,799,000 after acquiring an additional 3,201,087 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Performance

NYSE:PFE opened at $24.33 on Tuesday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The stock has a market capitalization of $138.33 billion, a P/E ratio of 17.63, a PEG ratio of 0.90 and a beta of 0.58. The company has a 50 day moving average price of $24.32 and a 200 day moving average price of $24.63. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The company had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. During the same quarter last year, the company posted $0.82 EPS. The firm's revenue was down 7.8% compared to the same quarter last year. Equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.07%. Pfizer's dividend payout ratio is presently 124.64%.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Redburn Atlantic lowered their target price on shares of Pfizer from $29.00 to $27.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 30th. Wolfe Research upped their price target on shares of Pfizer from $22.00 to $23.00 and gave the stock an "underperform" rating in a research report on Wednesday, April 30th. TD Cowen reduced their price target on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a research report on Tuesday, April 22nd. Morgan Stanley upped their price target on shares of Pfizer from $31.00 to $32.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 30th. Finally, BMO Capital Markets reduced their price target on shares of Pfizer from $36.00 to $30.00 in a research report on Thursday, April 17th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have given a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $28.55.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.